Literature DB >> 21849491

Role of AT₁ receptor-mediated salt retention in angiotensin II-dependent hypertension.

Steven D Crowley1, Jiandong Zhang, Maria Herrera, Robert Griffiths, Phillip Ruiz, Thomas M Coffman.   

Abstract

Activation of type 1 angiotensin II (AT(1)) receptors in the kidney promotes blood pressure elevation and target organ damage, but whether renal AT(1) receptors influence the level of hypertension by stimulating sodium retention or by raising systemic vascular resistance has not been established. In the current studies, we used a kidney cross-transplantation strategy to determine whether increased sodium reabsorption by AT(1) receptors in the kidney mediates the chronic hypertensive response to angiotensin II. We found this to be true. In addition, we also identified a second, nontrivial component of blood pressure elevation induced by activation of renal AT(1) receptors that is sodium-independent. As the kidney has the capacity to limit the transmission of elevated systemic blood pressure into the renal microcirculation, prior studies struggled to clearly discriminate the relative contributions of blood pressure elevation vs. activation of AT(1) receptors to hypertensive kidney injury. In our model, we found that rapid surges in blood pressure, which may overcome the kidney's capacity to prevent perturbations in renal hemodynamics, correlate closely with kidney damage in hypertension. Moreover, maximal kidney injury in hypertension may require activation of a pool of nonrenal, systemic AT(1) receptors. These studies provide insight into precise mechanisms through which AT(1) receptor blockade influences the progression of hypertensive kidney disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21849491      PMCID: PMC3213900          DOI: 10.1152/ajprenal.00305.2011

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  27 in total

1.  Divergent functions of angiotensin II receptor isoforms in the brain.

Authors:  R L Davisson; M I Oliverio; T M Coffman; C D Sigmund
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

2.  Use of a biological peptide pump to study chronic peptide hormone action in transgenic mice. Direct and indirect effects of angiotensin II on the heart.

Authors:  J P van Kats; D Methot; P Paradis; D W Silversides; T L Reudelhuber
Journal:  J Biol Chem       Date:  2001-09-10       Impact factor: 5.157

3.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

Review 4.  Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade.

Authors:  Karen A Griffin; Anil K Bidani
Journal:  Clin J Am Soc Nephrol       Date:  2006-07-12       Impact factor: 8.237

5.  A role for angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis of angiotensin II-dependent hypertension.

Authors:  Steven D Crowley; Young-Soo Song; Gregory Sprung; Robert Griffiths; Matthew Sparks; Ming Yan; James L Burchette; David N Howell; Eugene E Lin; Benson Okeiyi; Johannes Stegbauer; Yanqiang Yang; Pierre-Louis Tharaux; Phillip Ruiz
Journal:  Hypertension       Date:  2009-12-07       Impact factor: 10.190

6.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

7.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent.

Authors:  Karen A Griffin; Isam Abu-Amarah; Maria Picken; Anil K Bidani
Journal:  Hypertension       Date:  2003-02       Impact factor: 10.190

9.  Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damage.

Authors:  Norbert Henke; Ruth Schmidt-Ullrich; Ralf Dechend; Joon-Keun Park; Fatimunnisa Qadri; Maren Wellner; Michael Obst; Volkmar Gross; Rainer Dietz; Friedrich C Luft; Claus Scheidereit; Dominik N Muller
Journal:  Circ Res       Date:  2007-06-21       Impact factor: 17.367

10.  Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker.

Authors:  Anastasia Chrysostomou; Eugenia Pedagogos; Lachlan MacGregor; Gavin J Becker
Journal:  Clin J Am Soc Nephrol       Date:  2006-02-01       Impact factor: 8.237

View more
  31 in total

Review 1.  Evidence for a functional intracellular angiotensin system in the proximal tubule of the kidney.

Authors:  Brianne Ellis; Xiao C Li; Elisa Miguel-Qin; Victor Gu; Jia L Zhuo
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-14       Impact factor: 3.619

Review 2.  Renal autoregulation in health and disease.

Authors:  Mattias Carlström; Christopher S Wilcox; William J Arendshorst
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

3.  A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension.

Authors:  Jian-dong Zhang; Mehul B Patel; Young-Soo Song; Robert Griffiths; James Burchette; Phillip Ruiz; Matthew A Sparks; Ming Yan; David N Howell; Jose A Gomez; Robert F Spurney; Thomas M Coffman; Steven D Crowley
Journal:  Circ Res       Date:  2012-04-24       Impact factor: 17.367

4.  Age-related hypertension and salt sensitivity are associated with unique cortico-medullary distribution of D1R, AT1R, and NADPH-oxidase in FBN rats.

Authors:  Indira Pokkunuri; Gaurav Chugh; Imran Rizvi; Mohammad Asghar
Journal:  Clin Exp Hypertens       Date:  2015-01-06       Impact factor: 1.749

Review 5.  Renal effects of cytokines in hypertension.

Authors:  Yi Wen; Steven D Crowley
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-03       Impact factor: 2.894

Review 6.  Salt, Hypertension, and Immunity.

Authors:  A Justin Rucker; Nathan P Rudemiller; Steven D Crowley
Journal:  Annu Rev Physiol       Date:  2017-11-16       Impact factor: 19.318

7.  Phosphorylation by PKC and PKA regulate the kinase activity and downstream signaling of WNK4.

Authors:  Maria Castañeda-Bueno; Juan Pablo Arroyo; Junhui Zhang; Jeremy Puthumana; Orlando Yarborough; Shigeru Shibata; Lorena Rojas-Vega; Gerardo Gamba; Jesse Rinehart; Richard P Lifton
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-17       Impact factor: 11.205

Review 8.  Renal dopamine and angiotensin II receptor signaling in age-related hypertension.

Authors:  Gaurav Chugh; Indira Pokkunuri; Mohammad Asghar
Journal:  Am J Physiol Renal Physiol       Date:  2012-10-24

9.  The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.

Authors:  Mai Yanagi; Kouichi Tamura; Tetsuya Fujikawa; Hiromichi Wakui; Tomohiko Kanaoka; Masato Ohsawa; Kengo Azushima; Akinobu Maeda; Hiroyuki Kobori; Satoshi Umemura
Journal:  Hypertens Res       Date:  2012-11-15       Impact factor: 3.872

10.  Lack of specificity of commercial antibodies leads to misidentification of angiotensin type 1 receptor protein.

Authors:  Marcela Herrera; Matthew A Sparks; Adolfo R Alfonso-Pecchio; Lisa M Harrison-Bernard; Thomas M Coffman
Journal:  Hypertension       Date:  2012-11-12       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.